| HS Code | 201845 |
| Product Name | Combined Ovine Clostridial Diseases Vaccine, Inactivated (Dried Powder) |
| Product Category | Veterinary Grade API |
| Target Species | Ovine (sheep) |
| Vaccine Type | Inactivated (killed) clostridial disease vaccine |
| Physical Form | Dried powder (lyophilized) |
| Antigen Composition | Inactivated Clostridium perfringens types C and D, Clostridium tetani, Clostridium septicum, Clostridium novyi, and Clostridium chauvoei |
| Reconstitution Requirement | Must be reconstituted with sterile diluent before use |
| Route Of Administration | Subcutaneous or intramuscular injection |
| Adjuvant Type | Suitable veterinary-grade adjuvant such as aluminum hydroxide gel |
| Storage Conditions | Store at 2°C to 8°C, protected from light and moisture |
| Shelf Life | 24 months from date of manufacture when stored as recommended |
| Pharmacological Action | Induces active immunity by stimulating production of antibodies against clostridial exotoxins |
| Indications | Active immunization of sheep against enterotoxemia, black disease, tetanus, blackleg, and malignant edema |
| Dosage Regimen | Administer as a primary dose followed by periodic booster doses according to veterinary schedule |
| Finished Dosage Forms Compatibility | Tablets, injections, capsules, powders, granules, premixes, and solutions |
| Withdrawal Period | Zero days for sheep when used as a vaccine |
As an accredited Combined Ovine Clostridial Diseases Vaccine,Inactivated(Dried Powder) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in sterile, light-resistant glass vials with airtight rubber stoppers and aluminum seals, containing 100 g lyophilized powder per vial. |
| Container Loading (20′ FCL) | 20′ FCL of Combined Ovine Clostridial Diseases Vaccine, Inactivated (Dried Powder) Veterinary Grade API: palletized sealed drums/cartons in dry container. |
| Shipping | Ship as temperature-controlled, moisture-protected cargo in sealed, opaque containers. Ensure dry ice or cold packs per stability data, with tamper-evident seals. Include veterinary biologicals permit, SDS, and certificate of analysis. Avoid prolonged transit; use validated cold-chain carriers for injections, powders, or premix formulations. |
| Storage | Store at 2–8°C in a dry, well-ventilated area, protected from light and moisture. Keep container tightly sealed. Do not freeze. Use within manufacturer-specified shelf life after reconstitution or compounding, maintaining cold-chain conditions throughout handling, transport, and storage for tablets, injections, capsules, powders, granules, premix, or solutions. |
| Shelf Life | Shelf life is typically 24 months from manufacture when stored at 2-8°C, protected from light and moisture, ensuring vaccine efficacy. |
Low-temperature reconstitution of lyophilised combined ovine clostridial antigen matrix for late-gestation ewe immunisation is carried out at 2–8°C using sterile phosphate-buffered saline adjusted to pH 7.2, containing 0.85% w/v sodium chloride and 0.01% w/v thiomersal as preservative. The formulation addition ratio is not a uniform powder-to-diluent mass value; it is derived from batch potency concentration measured against the appropriate reference toxoid. A representative manufacturing formula begins with reconstitution of one part lyophilised powder in 9 parts sterile diluent by volume, followed by introduction of that antigen concentrate at 10% v/v into an aluminium hydroxide-adjuvanted vehicle standardised to 2.0–3.0 mg Al³⁺/mL in the final suspension. The pH is then adjusted to 6.3–7.0 with 0.1 M hydrochloric acid or sodium hydroxide under continuous low-shear agitation at 20–30 rpm for 45–90 min, allowing antigen adsorption to the aluminium hydroxide gel without shear collapse of the gel matrix. Aseptic filling is mandatory because sterile filtration through 0.22 µm membranes is not feasible for aluminium-adjuvanted particles, and terminal heat sterilisation would denature the clostridial toxoids and reduce batch potency below acceptable release limits. Release testing is anchored to Ph. Eur. 2.6.1 sterility, Ph. Eur. 2.6.14 bacterial endotoxins, and EU GMP Annex 2 biological active substance requirements. The terminal product is a ready-to-inject 2.0 mL subcutaneous suspension presented in 100 mL high-density polyethylene multidose vials with bromobutyl stoppers and aluminium crimp seals, administered 4–6 weeks before lambing to provide colostral passive transfer against C. perfringens type B beta toxoid, type D epsilon toxoid, and C. tetani toxoid in neonatal lambs.
For lamb marking and weaning cohorts entering mixed pasture systems, the same multivalent ovine clostridial powder is processed into a field-stable booster presentation where the controlling process variable is not antigenicity alone but sub-visible particle load in aluminium hydroxide suspension. The addition ratio at the compounding vessel is set at one part lyophilisate to 12.5 parts sterile diluent by volume; the resulting antigen concentrate is then transferred into a 200 L jacketed stainless steel vessel held at 2–8°C and blended with aluminium hydroxide gel to a final aluminium content of 2.0 mg Al³⁺/mL. The mixing system uses a bottom-sweep impeller at 12 rpm, not a rotor-stator homogeniser, because elevated shear above 3,000 rpm reduces the median gel particle size below 1 µm and can produce a slow-settling suspension that fails Ph. Eur. 2.9.19 particulate contamination requirements upon storage. On production-scale filling lines, this shear-induced change has been observed as a batch-to-batch increase in sub-visible particle counts when high-shear transfer pumps are substituted for low-pulse peristaltic pumps without requalification. Compliance for the booster line includes Ph. Eur. 2.6.1 sterility and VICH GL44 target animal safety data for the ovine species; the terminal product is a 2.0 mL subcutaneous booster dose in 50 mL high-density polyethylene multidose vials for lamb marking crews, stored at 2–8°C and protected from freezing.
Freezing of the filled vials causes irreversible aluminium hydroxide gel aggregation, visible sedimentation, and loss of antigen-adjuvant binding; batches exposed to temperatures below 0°C for more than 24 h must be discarded unless a formal freeze-thaw validation specific to the ovine clostridial powder demonstrates otherwise. Published data for this specific configuration is limited, so the freeze-thaw sensitivity threshold should be confirmed during downstream formulation development rather than extrapolated from unrelated aluminium-adjuvanted vaccines.
Confirmed C. perfringens type D enterotoxaemia outbreaks in mixed sheep and goat holdings require rapid deployment of adjuvanted vaccine without the lead time of liquid final-form logistics, and the lyophilised API is therefore supplied as a high-concentration field reconstitution pack. The addition ratio for emergency ring vaccination uses one part lyophilised powder reconstituted with 4 parts sterile physiological saline by volume to form a concentrated antigen suspension; that suspension is then transferred at 25% v/v into an aluminium hydroxide diluent to generate a 2.0 mL subcutaneous dose for sheep and goats at immediate risk. The downstream field process uses low-pulse pump reconstitution or vial adapter devices under shade at 2–8°C, with vortex mixing prohibited because vibrations above 2,500 rpm disrupt the gel structure and reduce vaccine residence time at the injection-site depot. Compliance obligations follow WOAH Terrestrial Manual recommendations for ovine clostridial vaccination in outbreak zones and remain subject to national veterinary pharmacovigilance reporting for any injection-site reactions. The terminal product is a short-shelf-life emergency multidose suspension in 50 mL cycloolefin copolymer bottles, depleted within 8 hours of reconstitution unless the manufacturer’s in-use stability data support a longer holding time. Cold chain excursions above 25°C for more than 72 hours are an operational boundary; the dried powder may tolerate transient temperature deviation better than the reconstituted aluminium hydroxide suspension, but potency retention must be confirmed by batch-specific stability data.
Downstream customers that purchase the dried powder for autogenous or private-label ovine vaccine formulation place the lyophilisation cycle itself under release pressure, because the powder must retain a porous cake structure, low residual moisture, and complete antigen integrity across multiple clostridial serotypes. The pre-lyophilisation addition ratio includes 3.0% w/v trehalose dihydrate and 1.0% w/v glycine as cryoprotectant and bulking matrix, with the antigen concentrate formulated to fill 1.0 g of dry powder per 20 mL Type I glass vial prior to freeze-drying. The lyophilisation cycle is controlled in a shelf freeze-dryer with shelf freezing to −45°C, primary drying at −10°C and 100 µbar, and secondary drying at +20°C until residual moisture measured by Ph. Eur. 2.5.12 falls below 3.0% w/w. Process failure modes on production-scale shelves include edge-vial collapse and non-uniform heat transfer across stainless steel trays, which can lift residual moisture in the centre of the batch above 3.0% w/w; this threshold is used because higher moisture accelerates loss of epsilon toxoid potency during room-temperature shipment. The dried powder is not compressed into oral tablets or capsules for sheep, because inactivated clostridial toxoids are degraded by ruminal and abomasal proteolysis before reaching intestinal inductive sites; the tablet and capsule denominations in API trade documentation describe powder flowability and compactability grades, not registered oral dosage forms for this antigen. Sterility testing follows Ph. Eur. 2.6.1, endotoxin testing follows Ph. Eur. 2.6.14, and the terminal product is a lyophilised API powder in Type I glass vials intended for reconstitution into injectable aluminium hydroxide suspension by licensed veterinary biological facilities.
The lyophilisation release matrix includes the following control points:
| Control parameter | Method or standard | Release criterion |
|---|---|---|
| Sterility | Ph. Eur. 2.6.1 | No growth after 14 days |
| Bacterial endotoxins | Ph. Eur. 2.6.14 | <2.0 EU per dose |
| Residual moisture | Ph. Eur. 2.5.12 (Karl Fischer) | <3.0% w/w |
| pH of reconstituted suspension | Ph. Eur. 2.2.3 | 6.3–7.0 |
| Aluminium content | Ph. Eur. 2.5.13 | 2.0–3.0 mg Al³⁺/mL |
Residual moisture, collapse temperature, and antigen adsorption are linked process limits; the collapse temperature of the formulation is not inferred from the diluent alone but is measured by freeze-drying microscopy, and published data for this specific multivalent ovine powder is limited, so each downstream laboratory must verify the glass transition of the maximally freeze-concentrated matrix before scaling from laboratory shelves to 10 m² production lyophilisers.
Where male lambs undergo tail docking and castration before 12 weeks of age, the tetanus toxoid fraction of the combined ovine clostridial powder becomes the most safety-critical component, and downstream formulation is directed toward consistent tetanus seroconversion rather than broad enterotoxaemia coverage alone. The addition ratio for this surgical prophylaxis presentation is one part lyophilised powder reconstituted with 9 parts sterile diluent, followed by final blending at 1:19 with phosphate-buffered aluminium hydroxide vehicle to deliver a 2.0 mL subcutaneous dose in which tetanus toxoid potency is standardised by challenge against the reference toxoid in accordance with the relevant veterinary vaccine monograph. The manufacturing process for this presentation uses aseptic fill into 20-dose amber glass vials under Grade A unidirectional airflow; low-shear peristaltic transfer is maintained at ≤150 mL/min to avoid denaturation of the tetanus toxoid at the liquid-air interface during filling. Compliance includes VICH GL44 target animal safety data for lambs and national animal welfare code obligations for marking procedures; the terminal product is a veterinary injectable suspension administered at or before the surgical event, with a second dose given 4 weeks later when primary immunisation has not been completed. Frozen storage is an incompatibility; exposure of the final vial below 0°C can cause irreversible aluminium hydroxide gel aggregation and a marked loss of tetanus toxoid adsorption, so cold-chain monitors are used rather than accepting visual precipitate as a release criterion.
Competitive Combined Ovine Clostridial Diseases Vaccine,Inactivated(Dried Powder) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
The product designated as Combined Ovine Clostridial Diseases Vaccine, Inactivated (Dried Powder) Veterinary Grade API is a lyophilized multicomponent antigen preparation intended as a starting material for downstream pharmaceutical manufacture of tablets, injections, capsules, powders, granules, premixes, and solutions. Supplier model codes encode valency count, inactivation chemistry, and stabilizer system; common variants cover 3-valent, 5-valent, 7-valent, and 8-valent combinations addressing Clostridium perfringens types A, B, C, and D, Clostridium septicum, Clostridium novyi type B, Clostridium chauvoei, Clostridium tetani, Clostridium sordellii, and Clostridium haemolyticum. The target disease coverage includes pulpy kidney caused by C. perfringens type D epsilon toxin, lamb dysentery caused by C. perfringens types B and C beta toxin, blackleg caused by C. chauvoei, black disease caused by C. novyi type B alpha toxin, tetanus caused by C. tetani neurotoxin, malignant oedema caused by C. septicum alpha toxin, and bacillary haemoglobinuria caused by C. haemolyticum. The lyophilized powder contains inactivated whole cells, toxoids, or subunit immunogens with residual mineral salts and cryoprotectants such as sucrose or trehalose at 2–5% w/v in the pre-lyophilization bulk. It is not a final dosage form; parenteral use requires aseptic reconstitution, and sterile filtration is not applicable to particulate whole-cell suspensions.
Release testing follows compendial methods validated for veterinary biologicals. The lyophilized cake is characterized for appearance as a white to off-white powder or cake, reconstitution time in water for injection at 20–25 °C not exceeding 10 min, residual moisture by Karl Fischer titration in accordance with Ph. Eur. 2.5.12 not more than 2.0% w/w, and residual free formaldehyde by Ph. Eur. 2.4.18 not more than 0.05% w/v after correction for blank. Sterility is evaluated by direct inoculation in fluid thioglycollate medium and soybean-casein digest medium according to Ph. Eur. 2.6.1; absence of mycoplasma by culture and indicator cell method according to Ph. Eur. 2.6.7; bacterial endotoxins by limulus amoebocyte lysate assay according to Ph. Eur. 2.6.14 with a limit assigned to the intended species dose, typically below 20 IU/mL after reconstitution to the registered concentration.
| Parameter | Specification | Method |
|---|---|---|
| Appearance | White to off-white powder or cake; no foreign matter | Visual inspection |
| Residual moisture | ≤ 2.0% w/w | Ph. Eur. 2.5.12 |
| Free formaldehyde | ≤ 0.05% w/v | Ph. Eur. 2.4.18 |
| Reconstitution time | ≤ 10 min at 20–25 °C | In-house validated method |
| Sterility | No growth | Ph. Eur. 2.6.1 |
| Mycoplasma | Absent | Ph. Eur. 2.6.7 |
| Bacterial endotoxins | ≤ 20 IU/mL after reconstitution | Ph. Eur. 2.6.14 |
| Potency | Supplier-defined ELISA titre and challenge survival | Fraction-specific immunogenicity assay |
| Safety | No target-species local or systemic reactions above threshold | Batch safety test per pharmacopoeial monograph |
Residual formaldehyde is controlled below the specified limit to minimize antigen cross-linking during storage. Potency testing for combined ovine clostridial fractions is not harmonized in international units across all valencies; therefore, batch release relies on fraction-specific ELISA titres and toxin neutralization assays in mice or sheep. The supplier’s certificate of analysis states the registered minimum titre for each component, and any single component falling below that titre renders the batch noncompliant even if total antigenic mass is unchanged.
Dry blending of the lyophilized API into tablet and capsule matrices is performed at relative humidity not exceeding 30% RH to prevent deliquescence of residual salts and antigen aggregation. Blend uniformity is tested in accordance with Ph. Eur. 2.9.40, and content uniformity of the finished tablets is assessed by Ph. Eur. 2.9.6. For capsules, the powder fill is adjusted for tapped density in the range 0.35–0.55 g/mL and Carr index determined by Ph. Eur. 2.9.36. Roller compaction or slugging is preferred over wet granulation because heat and moisture during aqueous granulation reduce toxin-derived antigen integrity; where wet granulation is unavoidable, inlet air temperature in fluid-bed drying is maintained below 35 °C and product temperature below 28 °C. Tablet compression force is established by correlation with friability tested according to Ph. Eur. 2.9.7, and disintegration is evaluated by Ph. Eur. 2.9.1 using water at 37 ± 2 °C. Published data for this specific configuration is limited, and each formulation must be supported by antigen recovery studies after compression.
Reconstitution for injectable manufacture is carried out in an aseptic environment meeting EU GMP Annex 1 requirements for Grade A zones under Grade B background with classification verified to ISO 14644-1:2015 Class 5 at rest. The reconstitution vehicle may be water for injection or a buffered saline medium with pH maintained at 6.5–7.5. The API is added slowly under low-shear mixing; high-shear dispersion is avoided because rotor-stator homogenization above 6,000 rpm can disrupt particulate antigen complexes and reduce potency. After reconstitution, the suspension is held at 2–8 °C and used within 4 h unless a longer hold time is validated by in-use stability. Sterile filtration is not appropriate for whole-cell or toxoid-containing suspensions; clarification may be performed only through a 100 µm screen to remove agglomerates. Terminal sterilization by moist heat is not used because heat-labile clostridial antigens denature above 40 °C. Final injectable products may be mixed with aluminium hydroxide or aluminium phosphate adjuvants, but adsorption time, ionic strength, and adjuvant concentration must be controlled because excessive antigen-binding capacity in multivalent formulations causes uneven distribution and local reactogenicity.
Premix and granule applications require dilution on an inert carrier such as spray-dried lactose or dextrose monohydrate. Geometric dilution is performed in three or more stages to achieve a relative standard deviation of antigen content below 5% as measured by ELISA quantification after extraction with phosphate-buffered saline containing 0.05% Tween 20. Solution dosage forms are prepared only from the water-soluble fraction of the lyophilized matrix; insoluble whole-cell components settle, and therefore continuous mixing during filling is required. Fill volume uniformity for solutions is verified by Ph. Eur. 2.9.17, and delivered dose uniformity for oral solutions is assessed by Ph. Eur. 2.9.40 after extraction.
The principal differentiation is the simultaneous presentation of multiple clostridial immunogens in a dried matrix. In a liquid monovalent C. perfringens type D toxoid, the antigen concentration can be standardized solely against the epsilon toxin reference; the combined powder requires resolution of antibody interference among alpha, beta, epsilon, and iota toxins, plus C. septicum alpha toxoid, C. novyi alpha toxoid, and tetanus toxoid. Antigenic competition between C. perfringens type D epsilon and C. tetani toxoids is mitigated by adjusting antigen premix ratios and by controlling aluminium adjuvant content in the final formulation, but the optimized ratio is product-specific and cannot be inferred from monovalent data. Compared with liquid bacterins, the dried powder reduces water activity to 0.2 or lower, which suppresses hydrolytic degradation pathways; however, the freeze-drying process may reduce the recovery of labile toxoids by 0.1–0.3 log₁₀ unless cryoprotectants such as sucrose or trehalose are present at 2–5% w/v.
| Attribute | Dried powder combined API | Liquid combined bacterin |
|---|---|---|
| Physical state | Lyophilized powder or cake | Aqueous suspension |
| Water activity | ≤ 0.2 | 0.95–0.98 |
| Storage temperature | 2–8 °C, desiccated | 2–8 °C, avoid freezing |
| Downstream use | Dry blends, tablets, capsules, premix; reconstitution needed for injection | Ready for injection after dilution |
| Antigen complexity | 3–8 valencies, antigenic competition risk | 1–8 valencies, higher hydrolysis risk |
| Packaging | Amber glass under nitrogen, oxygen below 2% v/v | Polymer or glass vials, no oxygen headspace issue |
| Critical controls | Residual moisture, reconstitution time, collapse temperature | pH, sedimentation, preservative content, endotoxin |
The inactivated whole-cell fraction contributes to higher endotoxin load than purified toxoid products; therefore, the endotoxin limit must be set according to the maximum intended ovine dose and residual cell-wall components. Differences also arise in packaging: the dried powder is filled under nitrogen headspace with oxygen below 2% v/v, whereas liquid preparations use nitrogen or preservative to control oxidative degradation. The powder form allows formulation into granules and premixes, but direct equivalence to liquid injectable efficacy cannot be assumed without serological challenge studies. Gelatin capsule shells are cautioned against for formaldehyde-rich powders because residual aldehyde can cross-link gelatin and delay disintegration at 37 ± 2 °C; hypromellose capsules are preferred for moisture-sensitive powder blends.
Antigen integrity during drying is controlled by freeze-drying microscopy and differential scanning calorimetry. The collapse temperature of the formulation is determined by freeze-drying microscopy at heating rate 0.5 °C/min; the product is frozen to -45 °C and primary drying is conducted at product temperature 2–3 °C below the collapse temperature, with chamber pressure 0.10–0.20 mbar. Secondary drying is terminated when product moisture by Karl Fischer is below 2.0% w/w. Batch-to-batch variance in residual moisture and antigen recovery is monitored by control charts; a rise in residual moisture above 2.5% w/w triggers quarantine because moisture above this threshold accelerates lyophilized cake shrinkage and loss of toxoid potency. The API is packed in amber glass vials under nitrogen headspace with oxygen below 2% v/v; closure integrity is tested by vacuum decay or dye ingress.
The API is incompatible with amine-containing buffers at pH above 8.0, strong oxidizing agents, and prolonged exposure to temperatures above 40 °C. During tablet manufacture, magnesium stearate above 1.0% w/w reduces disintegration and antigen dissolution; compression force and dwell time are validated by content uniformity and ELISA recovery. The product should be stored at 2–8 °C in a desiccated container and used before the expiry stated on the certificate of analysis; unopened vials should be allowed to equilibrate to 20–25 °C before opening to avoid condensation. Published data for this specific configuration is limited; each downstream formulation must therefore be supported by batch-scale antigen recovery studies and target-species immunogenicity testing.
